» Articles » PMID: 39482101

Efficacy of Dextrose Prolotherapy on Temporomandibular Disorder: a Retrospective Study

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Dextrose prolotherapy is one of the most promising minimally invasive interventions for temporomandibular disorder (TMD), particularly in refractory cases where other conservative treatments have failed. The purpose of this study was to demonstrate the efficacy of a new treatment, temporomandibular joint (TMJ) prolotherapy, in patients with TMD to alleviate symptoms.

Materials And Methods: A retrospective analysis was conducted on TMD patients with chronic pain who did not respond to conventional treatments. TMJ prolotherapy was performed using hypertonic dextrose in the TMJ area, targeting the retrodiscal attachment tissue, anterior disc attachment tissue, lateral capsule, origin of the masseter muscle, and the stylomandibular ligament. Pain or discomfort intensity in the TMJ was evaluated using a numerical rating scale (NRS). Maximum mouth opening and subjective satisfaction were also analyzed.

Results: Nineteen patients (6 males, 13 females, average age 43 years) participated in this study. All patients experienced pain improvement with a maximum of three prolotherapy sessions. The initial mean NRS was 5.7, which ultimately decreased to a final mean TMJ discomfort score of 1.7 postintervention. The patients' maximum mouth opening increased from an initial 34.5 mm to 38.8 mm, and they reported positive satisfaction with the prolotherapy treatment. The clinical outcomes were positive regardless of main origin of TMD symptoms.

Conclusion: Hypertonic TMJ prolotherapy is an effective minimally invasive intervention for TMJ disorders with chronic pain.

Citing Articles

Response to the letter regarding prolotherapy in temporomandibular disorders.

Ku J J Korean Assoc Oral Maxillofac Surg. 2025; 51(1):69-70.

PMID: 40017078 PMC: 11880668. DOI: 10.5125/jkaoms.2025.51.1.69.


Comment on: Efficacy of dextrose prolotherapy on temporomandibular disorder.

Merchant Y J Korean Assoc Oral Maxillofac Surg. 2025; 51(1):67-68.

PMID: 40017077 PMC: 11880674. DOI: 10.5125/jkaoms.2025.51.1.67.

References
1.
Rabago D, Slattengren A, Zgierska A . Prolotherapy in primary care practice. Prim Care. 2010; 37(1):65-80. PMC: 2831229. DOI: 10.1016/j.pop.2009.09.013. View

2.
Yilmaz O, Candirli C, Balaban E, Demirkol M . Evaluation of success criteria for temporomandibular joint arthrocentesis. J Korean Assoc Oral Maxillofac Surg. 2019; 45(1):15-20. PMC: 6400701. DOI: 10.5125/jkaoms.2019.45.1.15. View

3.
Khan S, Kumar A, Varshney M, Trikha V, Yadav C . Dextrose prolotherapy for recalcitrant coccygodynia. J Orthop Surg (Hong Kong). 2008; 16(1):27-9. DOI: 10.1177/230949900801600107. View

4.
Abouelhuda A, Khalifa A, Kim Y, Hegazy S . Non-invasive different modalities of treatment for temporomandibular disorders: review of literature. J Korean Assoc Oral Maxillofac Surg. 2018; 44(2):43-51. PMC: 5932270. DOI: 10.5125/jkaoms.2018.44.2.43. View

5.
Dasukil S, Shetty S, Arora G, Degala S . Efficacy of Prolotherapy in Temporomandibular Joint Disorders: An Exploratory Study. J Maxillofac Oral Surg. 2021; 20(1):115-120. PMC: 7855124. DOI: 10.1007/s12663-020-01328-9. View